Materials and methods: This prospective, noninterventional, observational cohort study will enrol patients aged 12 years with physician- and laboratory-confirmed HAE newly initiating on-label garadacimab (200 mg subcutaneous once monthly) from ~ 30 centres in Europe, the UK, North America and the AsiaPacific region (target enrolment: 200 patients)
[DOI] [PubMed] [Google Scholar] 105.Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., Kanai Y., Hediger M.A., Wang Y., Schielke J.P., et al
Vildagliptin attenuates Huntingtons disease through activation of GLP-1 Receptor/PI3K/Akt/BDNF pathway in 3-Nitropropionic acid rat model
Chris Centeno summarized in this article a review of the total PRP studies for knee osteoarthritis, and quantified those with favorable results and unfavorable results
Ultimately, the future of peptide research hinges on this kind of meticulous, safety-first approach